Meeting
2011 ASCO Annual Meeting
A randomized, double-blind, placebo-controlled cross over trial of the effect on quality of life (QOL) of continuing dexamethasone beyond 24 hours following moderately emetogenic chemotherapy in women with breast cancer.
Authors
J. L. Vardy
Sydney Cancer Centre, Sydney, Australia
J. L. Vardy , G. R. Pond , A. Dodd , D. Warr , B. Seruga , M. J. Clemons , L. Bordeleau , I. Tannock
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Supportive Care
Clinical Trial Registration Number
NCT00152867
Citation
J Clin Oncol 29: 2011 (suppl; abstr 9020)
Abstract #
9020
Poster Bd #
4
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Impact of rolapitant on quality of life (QoL) in patients (pts) receiving highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC).
First Author: Martin Chasen
Poster
2023 ASCO Annual Meeting
A phase III, double-blind, non-inferiority, randomized controlled trial of antiemetic prophylaxis for highly emetogenic chemotherapy without dexamethasone: CINV POD study.
First Author: Venkatraman Radhakrishnan
Poster
2022 ASCO Annual Meeting
Olanzapine with or without an NK-1 receptor antagonist for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy: A phase III randomized, double-blind, placebo-controlled trial (ALLIANCE A221602).
First Author: Rudolph M. Navari
Poster
2021 ASCO Annual Meeting
A randomized, double-blind, multicenter, phase III study of fosnetupitant for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving doxorubicin-cyclophosphamide/epirubicin-cyclophosphamide(AC/EC) based highly emetogenic chemotherapy: CONSOLE-BC.
First Author: Junji Tsurutani